Floatz logo

IBUPROFEN

Pain Management

Universidad Europea de MadridSmall moleculePhase 4 / ApprovedDormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
81/ 100

Competitive context

14 Active assets in the Pain Management cohort.

Asset / SponsorPhaseRating
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
Charitable Organisation Charitable Fund Superhumans (Co Cf Superhumans)
Phase 4BB
NEPENTHE
Michał Borys
Phase 4BB
METAMIZOLE
Michał Borys
Phase 4BB
(RS)-KETOPROFEN
Michał Borys
Phase 4BB
ETHYLICUM
The University of Hong Kong
Phase 4B

View all 18 →

Same molecule, other indications

IBUPROFEN is also rated in:

chronic pain syndromeDormant
BBB
Indicative ·
72 / 100
View asset →
migraine disorderDormant
BBB
Indicative ·
72 / 100
View asset →
relapsing-remitting multiple sclerosisDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →